A list of representative drugs explored in pharmacological treatments of polyQ diseases is provided in Table , along with their suggested mechanism and targeted diseases. Huntington's disease is currently the only polyQ disease that has US FDA approved treatments. Three drugs, Xenazine (tetrabenazine) , Austedo (deutetrabenazine) both immediate and extended release 143-145 , and Ingrezza (valbenazine) 146 are approved for the treatment of the movement disorder chorea, caused by Huntington's disease. Xenazine received approval in 2008, followed by Austedo in 2017, along with Austedo XR and Ingrezza last year in 2023.